Biomarker and imaging responses to spironolactone in subclinical diabetic cardiomyopathy. (28th January 2014)

• Record Type: Journal Article
• Authors: Jellis, Christine L.; Sacre, Julian W.; Wright, Jeremy; Jenkins, Carly; Haluska, Brian; Jeffriess, Leanne; Martin, Jennifer; Marwick, Thomas H.
• Is Part Of: European heart journal. Volume 15:Number 7(2014:Jul.)
• Page Start: 776
• Page End: 786
• Publication Date: 2014-01-28
• Subjects: Pro-collagen biomarkers -- diabetic cardiomyopathy -- myocardial fibrosis -- diastolic dysfunction -- backscatter -- T1 mapping -- spironolactone; Cardiovascular system -- Imaging -- Periodicals; Heart -- Imaging -- Periodicals; 616.10754
• DOI: 10.1093/ehjci/jeu013
• Languages: English
• ISSNs: 2047-2404

Abstract

Abstract: Background: Subclinical diabetic cardiomyopathy (DCM) is frequent in asymptomatic subjects with type 2 diabetes (T2DM). We sought the response of functional and fibrosis markers to therapy in a trial of aldosterone antagonism for treatment of DCM. Methods: Biochemical, anthropometric, and echocardiographic data were measured in 225 subjects with T2DM. Myocardial function was evaluated with standard echocardiography and myocardial deformation; ischaemia was excluded by exercise echocardiography. Calibrated integrated backscatter and post-contrast T1 mapping from cardiac magnetic resonance imaging were used to assess myocardial structure. Amino-terminal propeptides of pro-collagen type I (PINP) and III (PIIINP), the carboxy-terminal propeptide of pro-collagen type I (PICP) and transforming growth factor beta-1 were measured from peripheral blood or urine to assess myocardial collagen turnover. Results: Diastolic dysfunction was identified in 81 individuals, of whom 49 (25 male, age 60 ± 10 years) were randomized to spironolactone 25 mg/day or placebo therapy for 6 months. Groups were well-matched at baseline. Spironolactone therapy was associated with improvements in diastolic filling profile (Δpeak E wave velocity −4 ± 15 vs. 9 ± 10 ms, P = 0.001; Δ E / A ratio −0.1 ± 0.3 vs. 0.2 ± 0.2, P < 0.001) and cIB values (−21.2 ± 4.5 dB vs. −18.0 ± 5.2 dB, P = 0.026; ΔcIB −5.1 ± 6.8 vs. −1.3 ± 5.2, P = 0.030). ΔcIB was independently associated with spironolactone therapy (β = 0.320, P = 0.026) but not Δblood pressure. With intervention, pro-collagen biomarkers (ΔPINP P = 0.92, ΔPICP P = 0.25, ΔPIIINP P = 0.52, and ΔTGF-β1 P = 0.71) and T1 values ( P = 0.54) remained similar between groups. Conclusions: Spironolactone-induced changes in myocardial structure and diastolic properties in DCM are small, and are unassociated with changes in collagen biomarkers or T1 values.